

CLINICAL EVALUATION STUDY



Evident is an Irish health technology company co-founded by Kevin Barrett (CEO) and Rob Brown (CTO). A winner of the HIHI.AI Call 2025, Evident has developed an AI-powered clinical trial recruitment platform designed to help healthcare organisations identify eligible patients for clinical trials more efficiently.

The platform uses artificial intelligence, including large language models, to analyse unstructured clinical data and generate ranked lists of potentially eligible participants, while ensuring all patient data remains securely within hospital systems through an on-premises architecture.



Kevin Barrett,
CEO

Rob Brown
CTO

About HIHI.AI

Health Innovation Hub Ireland (HIHI) recognises the potential of artificial intelligence (AI) to improve healthcare delivery, patient outcomes, and system efficiency. Growing demand on health services and increasing complexity in care highlight the need for innovative, data-driven solutions. HIHI is committed to supporting the development of AI-enabled products and services across clinical, operational, and administrative domains.

The field of AI in healthcare is rapidly evolving, encompassing applications such as diagnostic support, predictive

analytics, workflow optimisation, and patient engagement tools. These technologies span patient care, hospital operations, laboratory services, and broader system management, supporting more efficient and responsive healthcare systems.




The Healthcare Challenge

Patient recruitment remains one of the greatest barriers to successful clinical trial delivery. Across Irish healthcare settings, identifying eligible participants is largely a manual process involving reviews of multiple disconnected clinical systems, paper records and local databases. Research teams often screen large numbers of patients to identify a small cohort who meet trial criteria, resulting in significant time pressures and missed recruitment opportunities.

This challenge is particularly acute in time-sensitive environments such as intensive care, where recruitment windows may be as short as 12 hours. The fragmented nature of healthcare data systems, including Evolve, MetaVision, Diamond, NCIS and paper-based records, further complicates patient identification. As a result, potentially suitable participants may be overlooked, limiting trial recruitment, delaying research and reducing patient access to innovative treatments.



The Health Solution



Evident has developed an AI-powered platform that automates the identification of patients who may be eligible for clinical trials. It analyses clinical data from multiple sources and generates ranked lists of potential participants for review. Importantly, the technology is designed to support rather than replace clinical judgement, with all recommendations traceable back to source records.

Key features include:

- Automated overnight cohort discovery across clinical data sources.
- AI-assisted identification of potentially eligible trial participants.
- Screening of individual patients against multiple concurrent clinical trials.
- On-premises deployment ensuring patient data remains onsite.
- Integration capability across multiple healthcare information systems.

By reducing the burden of manual screening, Evident aims to improve recruitment efficiency, minimise missed enrolments and support broader access to clinical research opportunities.

HIHI Role

HIHI designed and facilitated an independent clinical evaluation of the Evident platform involving stakeholders from the Critical Care Research Group, Clinical Research Facility, Institute of Clinical Trials, and HSE West Northwest. Three structured evaluation sessions were conducted between April and May 2026, bringing together clinical researchers, principal investigators, operational leads and data specialists.

The evaluation explored current patient identification and recruitment workflows and the perceived value and

feasibility of the Evident platform. It also explored data governance, GDPR and regulatory considerations and delved into system integration requirements, implementation challenges and conditions required for future pilot deployment within Irish healthcare settings. By convening relevant stakeholders in a structured and neutral environment, HIHI enabled the company to gather valuable insights, validate market need and identify the key requirements for successful implementation.

Outcome Report

The evaluation confirmed that manual patient identification is a significant and widely recognised challenge across Irish clinical research environments. Participants consistently reported that current recruitment processes are labour-intensive and can result in missed enrolments. The concept of automated cohort discovery was positively received across all stakeholder groups.

Key findings included:

- Strong validation of the need for automated patient identification tools.
- Positive feedback on screening patients across multiple clinical trials simultaneously.
- Recognition that the platform could improve recruitment efficiency and trial feasibility assessments.
- Strong support for the platform's on-premises architecture from a data governance perspective.
- Recognition of the potential to support greater equity in access to clinical trials across geographic regions.

The evaluation also highlighted several important requirements for future deployment, including HSE IT engagement, regulatory validation, GDPR compliance, AI model validation and integration with existing clinical information systems. Overall, the findings position Evident as a promising solution capable of addressing a clear unmet need within Irish clinical research and supporting more efficient and equitable trial recruitment.

Testimonial

"Working with HIHI enabled Evident to conduct a structured clinical evaluation of our platform with three focus groups involving representative end users. The process gave us direct access to valuable clinical and operational feedback from the people who would ultimately use the product in practice. This helped us validate the underlying need for Evident, better understand current clinical trial identification and screening workflows, and identify the practical requirements for successful implementation within healthcare settings. The feedback also allowed us to refine the platform, strengthen our value proposition and ensure that future development remains closely aligned with real-world clinical needs."

The support provided by Health Innovation Hub Ireland has been valuable in moving Evident from a technology-led concept towards a solution shaped by end-user experience and healthcare delivery requirements."
Kevin Barrett, Evident CEO